Zoladex LA is already approved in 78 countries and has replaced the monthly depot in the majority of patients on this therapy in all major markets, due to the benefits offered. Benefits of the longer-acting formulation include a more convenient therapy for prostate cancer patients and improved compliance.

Zoladex is a widely prescribed LHRHa therapy administered by a subcutaneous depot injection. LHRHas work by reducing testosterone production. Zoladex is one of the world’s leading therapies for prostate cancer, with proven survival data, offering similar overall survival benefits and improvements in quality of life compared to surgical castration (orchidectomy).

In addition, in the adjuvant setting, Zoladex is the only LHRHa demonstrating proven disease-free survival as well as overall survival benefits, compared with primary treatment alone.

First launched in 1987, Zoladex is available in more than 100 countries. Zoladex is the world’s number three anti-cancer drug with indications in prostate and breast cancer and the top oncology product for AstraZeneca, with annual sales in excess of $700 million. Japan is AstraZeneca’s second biggest market.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of $15.8 billion and leading positions in sales of gastrointestinal, oncology, anaesthesia including pain management, cardiovascular, central nervous system (CNS) and respiratory products.